美國
證券交易所
華盛頓特區20549
表格
公司當前報告
根據《證券交易法》第13或15(d)條款 執行
1934年證券交易法
報告日期
(所報告的最早事件日期):
（按其章程規定的確切名稱）
| （註冊或設立所在地，?其它管轄區) （公司註冊） |
（委員會文件編號） | 稅務局僱主 |
(總部地址，包括郵政編碼)
(
(註冊人的電話號碼，包括區號)
無數據
（自上次報告以來名稱或地址發生變更，填寫舊名稱或地址）
根據證券法第12(b)條註冊的證券：
| 每個類別的名稱： | 交易標的 | 註冊在每個交易所的名稱： | ||
| 本基金尋求於東歐地區註冊的主要權益關聯發行人的長期升值投資。 | ||||
| 本基金尋求於東歐地區註冊的主要權益關聯發行人的長期升值投資。證券交易所 LLC |
根據《證券法》第425條規定的書面通信（17 CFR 230.425)
| 根據證券法規則425條（17 CFR 230.425）的書面 通信 |
| 根據交易所法規定14a-12條的招股材料(17 CFR 240.14a-12) |
| 根據交易所法規定14d-2(b)條的發起前通信(17 CFR 240.14d-2(b)) |
| 根據《交易所法》規則13e-4(c)進行的開篇通訊（17 CFR 240.13e-4(c)) |
請勾選表示註冊人是否符合1933年證券法規定的新興成長公司（第405條規則，本章第230.405條）或1934年證券交易法規定的規則1202億.2（本章第2401億.2條）。
新興成長公司
如果作爲新興成長公司，標註檢查標記表示註冊人選擇遵從根據《交易所法案》第13(a)條規定提供的任何新的或修訂財務會計準則的延遲過渡期。
項目1.01.簽訂重大合同。
2024年8月27日，DatChat公司與Judaopta LLC（以下簡稱「賣方」），一家特拉華州有限責任公司，簽署了一份資產購買協議，在此協議下，DatChat公司從賣方獲得了以下資產：（i）某些軟件（以下簡稱「RenAI軟件」），這是一種用於媒體庫組織的人工智能（AI）工具，具有使用AI標記和重命名PC和MAC設備圖像的能力，並與Gemini、OpenAI和Claude集成功能，以及（ii）某些域名，作爲交換條件，DatChat公司將8,000,000股受限制的Dragon Interact, Inc.普通股轉讓給賣方。
前述的採購協議摘要並不意味着是完整的描述，其全部內容均受附件10.1所附的採購協議的全文描述所限，並以此參考。
8.01其他事件。
2024年8月29日，公司發佈新聞稿宣佈購買協議和資產收購。新聞稿副本作爲附件99.1附上，並通過引用納入本文件。
項目9.01 基本報表和展示文件。
(d) 附件
| 展示編號 | 描述 | |
| 10.1#* | 2024年8月27日，DatChat，Inc.和Judaopta LLC.之間簽訂的資產購買協議。 | |
| 99.1 | 2024年8月29日的新聞發佈。 | |
| 104 | 封面交互數據文件（嵌入在Inline XBRL文檔中）。 |
| # | 根據S-K法規第601(b)(10)條，通過使用星號標記已將此展品的某些機密部分省略，因爲經確認的機密部分(i)不重要，且(ii)如果公開披露會對競爭造成危害 |
| * | 本展品的時間表（以及類似附件）已根據《S-k法規》第601（b）（2）項的規定被省略。公司同意在證券交易委員會要求時提供任何被省略的時間表（或類似附件）的補充副本。 |
-1-
簽名
根據《證券交易法》的規定，註冊人已授權其代表簽署本報告。
| DATCHAt，INC。 | ||
| Loss after tax for FY2024 was US$8800萬, a 7% increase compared to US$8190萬 for FY2023. The net loss attributable to ordinary shareholders was 8.91 US cents per share for FY2024, compared with 10.53 US cents per share for FY2023. Conference Call There will be a webcast today, beginning at 8.30am AESt (Thursday, August 29); 6.30pm EDt (Wednesday, August 28). It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2024/ The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late- stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, biologic-resistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes 1. Jagasia m et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749 2. Abedin S, et al. Ruxolitinib resistance or intolerance in steroid-refractory acute graft versus-host disease — a real-world outcomes analysis. British Journal of Haematology, 2021;195:429–43. 3. Wittenberg RE, Gauvreau k, Leighton J, Moleon-Shea m, Borow Km, Marx GR, Emani Sm, Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndrome, JTCVS Open Volume 16, Dec 2023, doi: https://doi.org/10.1016/j.xjon.2023.09.031 4. Symons JD, Deeter L, Deeter N, et al. Effect of continuous-flow left ventricular assist device support on coronary artery endothelial function in ischemic and nonischemic cardiomyopathy. Cir Heart Fail 2019; 12:e006085. DOI: 10.1161/CIRCHEARTFAILURE.119.006085. 5. Using Reserve Bank of Australia (RBA) published exchange rate from June 30, 2024 of 1A$:0.6624US$. 6. TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd. 7. TEMCELL sales by our Licensee are recorded in Japanese Yen before being translated into USD for the purposes of calculating the royalty paid to Mesoblast. Results have been adjusted for the movement of the USD to Japanese Yen exchange rate from 1USD:140.01 Yen for the twelve months ended June 30, 2023 to 1USD:151.75 Yen for the twelve months ended June 30, 2024. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our | 通過： | / s / Darin Myman |
| 姓名： | Darin Myman | |
| 標題： | 首席執行官 | |
-2-